Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think

3 min

Published on: Jun 23, 2026

At this year’s ACMG Annual Conference, I attended a session that has stayed with me—one that revealed, with heartbreaking clarity, the consequences that even brief interruptions in treatment access can have for people living with rare diseases. The discussion centered on clinical trials and premature discontinuation, but what resonated most was a single patient story from a clinical trial for a serious rare disease.

The patient had lived for years with the profound daily challenges of a deficiency that caused unrelenting fatigue and stamina so limited it prevented full time work. A commonly available treatment had offered some relief, but only partially and never enough. The condition remains serious, progressive, and unforgiving.

The arrival of an experimental drug marked a turning point. For patients, this was not simply another treatment option. It was the first glimpse of hope. That hope became real for this individual through a clinical trial. The transformation was immediate and profound. For the first time in years, the patient was able to work full time and actively participate in life rather than merely endure it.

In the winter, the final dose was administered. The long term extension was expected to begin the following spring—just a short pause, or so it seemed. But then the asset was sold. The study ended abruptly. And patients were left without treatment.

Return to Insights Center

Back

Access exclusive insights

Harness the power of clinical development with exclusive insights from our experts at Parexel

Would you like to hear from us in the future?

Stay connected with Parexel!

Accept

Decline